On April 24, 2020 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that the Company expects to report business results for the first quarter 2020 after 5:00 p.m. ET on Tuesday, May 5, 2020 (Press release, Supernus, APR 24, 2020, View Source [SID1234556589]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Senior Vice President and Chief Financial Officer, will host a conference call to present the first quarter 2020 business and financial results on Wednesday, May 6, 2020 at 9:00 a.m. ET. Following management’s prepared analysis and discussion of business results, the call will be open for questions.

A live webcast will be available at www.supernus.com.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in: (877) 288-1043
International dial-in: (970) 315-0267
Conference ID: 9899405
Conference Call Name: Supernus Pharmaceuticals First Quarter 2020 Earnings Conference Call
Following the live call, a replay will be available on the Company’s website under the ‘Investors Relations’ section. The webcast will be available on the Company’s website for 60 days following the live call.

On April 24, 2020 Rasna Therapeutics, Inc. (OTCQB: RASP), a development stage biotechnology company focused on the development of disease-modifying drugs for hematological malignancies, reported it has sold all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin D (Act D; a.k.a. Dactinomycin) to Tiziana Life Sciences plc pursuant to an asset purchase agreement in exchange for an upfront payment of $120,000 and milestone payments of up to an aggregate $630,000 (Press release, Rasna Therapeutics, APR 24, 2020, View Source [SID1234556588]). Rasna is continuing to develop NPM1-mutated AML through direct and indirect disease-modifying approaches as well as inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, as a promising and novel approach against AML.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About NP-Act D

Actinomycin D, an inhibitor of RNA-dependent RNA polymerase, is a potent antibiotic with therapeutic utilities in infectious diseases. Actinomycin was approved for medical use in the United States in 1964. It is on the World Health Organization’s List of Essential Medicines, the safest and most effective medicines needed in a health system. Currently, the drug is primarily used for infectious diseases but recent studies suggest potential of this drug in certain cancers as well. However, intravenously administered Actinomycin D is known to produce severe toxicities, its therapeutic utility has been limited. The nanoparticle-based Actinomycin D (NP-ACT D) is formulated to control and slow release of Act D such that the Cmax in blood can be adjusted. In animal studies, NP-Act D was found to produce minimal toxicities and it was found to safe and well-tolerated.

On April 24, 2020 Pfenex Inc. (NYSE American: PFNX) reported that it will report its financial results for the first quarter ended March 31, 2020, after the market close on Thursday, May 7, 2020 (Press release, Pfenex, APR 24, 2020, View Source [SID1234556587]). Pfenex will host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call & Webcast
Thursday, May 7th @ 1:30 PM Pacific Time (4:30 PM Eastern Time)
Domestic: 888-220-8451
International: 856-344-9221
Conference ID: 3922891
Webcast: View Source

Webcast replays available through May 14th:
Webcast: View Source

On April 24, 2020 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that it will host a conference call and webcast to report its first quarter financial results on Friday, May 1, 2020, at 8:30 a.m. ET (Press release, GlycoMimetics, APR 24, 2020, View Source [SID1234556586]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4567397. A webcast replay will be available via the "Investors" tab on the GlycoMimetics website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, participant code 4567397.

We encourage speakers and participants to connect early to ensure that all callers are able to connect. Perhaps, include language in earnings announcement and release to remind all speakers/participants to dial in 15 minutes prior to the call start time. Also, any callers who would like to ask questions, to queue early in the call.

On April 24, 2020 Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the "Company") reported that Epi proColon, the first and only FDA-approved blood-test for colorectal cancer (CRC) screening, has been included in the 2020 National Comprehensive Cancer Network (NCCN) CRC Guidelines (Press release, Epigenomics, APR 24, 2020, View Source [SID1234556585]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NCCN updated their 2020 CRC guidelines in a manner consistent with Epi proColon’s (Septin9) FDA-approved indications. The new NCCN guidelines state that although the mSEPT9 blood test is "not recommended for routine screening", it however "can be considered for patients who refuse other screening modalities". Epi proColon’s FDA approved indications for use are the following:

The Epi proColon test is indicated to screen adults of either sex, 50 years or older, defined as average risk for CRC, who have been offered and have a history of not completing CRC screening. Tests that are available and recommended in the USPSTF 2008 CRC screening guidelines should be offered and declined prior to offering the Epi proColon test. Patients with a positive Epi proColon test result should be referred for diagnostic colonoscopy. The Epi proColon test results should be used in combination with physician’s assessment and individual risk factors in guiding patient management.

"We are pleased with the inclusion of Epi proColon in the 2020 NCCN guidelines in close alignment with the blood test’s FDA-approved intended use," stated Epigenomics CEO Greg Hamilton. "NCCN’s latest guideline update further highlights the significant opportunity to address the over 30 million Americans who currently do not participate in CRC screening. We believe Epi proColon has the potential to significantly increase the screening rates and most importantly save lives."

Epigenomics AG looks forward to future NCCN guidelines to include key data such as an annual recommendation for the test interval, which could be based on outcomes from the recently published microsimulation paper (D’Andrea et.al. epub – Nov. 2019 – Cancer Medicine. 2020; 9:824.), which was not referenced by the 2020 NCCN guidelines. These data demonstrate that annual Septin9 screening results in comparable long-term benefits and less harms as compared to the "gold standard" colonoscopy every ten years. The Cancer Medicine publication was not included as part of this latest 2020 NCCN guideline as it was published shortly after their literature review cut-off date and subsequent panel review meeting.